Identifying Heart, Lung, and Blood Disease-Causing Variants
Page 2

The diseases that are included in this inquiry are early onset myocardial infarction, anthropometry, extremely low density lipoprotein, early onset ischemic stroke, extrelemy low or high blog pressure, chronic obstructive pulmonary diseases, cystic fibrosis, pulmonary hypertension, asthma, and acute lung injury.

The Identifying Heart, Lung, and Blood Disease-Causing Variants Program seeks to collaborate with population geneticists, epidemiologists, statistical geneticists, disease experts, and laboratory genomic experts to gain a more thorough and efficient understanding of the newly established exome variants associated with the complex diseases that are identified by the National Heart, Lung, and Blood Institute.

The agencies funding this program is set to administer a total of $1,515,000 per year to support the activities of the program in focus.

In order to be eligible to submit an application for this program you should be any of the following:

a) Higher Education Institutions such as Public/State Controlled Institutions of Higher Education and Private Institutions of Higher Education

b) Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions

c) Nonprofit organizations other than institutions of higher education

d) For-Profit Organizations such as Small Businesses

e) State Governments, County Governments, City or Township Governments, Special District Governments, Indian/Native American Tribal Governments (Federally Recognized), and Indian/Native American Tribal Governments (Other than Federally Recognized)

f) Independent School Districts, Public Housing Authorities/Indian Housing Authorities, Native American Tribal Organizations (other than Federally recognized tribal governments), Faith-based or Community-based Organizations, and Regional Organizations.

Identifying Heart, Lung, and Blood Disease-Causing Variants
  Back to Page 1

About The Author The TopGovernmentGrants Editorial Staff maintains one the most comprehensive Websites offering information on government grants and federal government programs. The staff also provides resources to other Websites with information on environmental grants and grants for youth programs.

Additional Resources

category - Health Grants

Family Planning Services Grants
OPHS has recently established a funding opportunity entitled Family Planning Services Grants, a program wherein the OPHS, along with the HHS, will award grants to eligible individuals who seek to operate voluntary family planning services projects that would provide family planning services to everyone who desires to avail of such services, including low-income families in under-served areas.

---

Biomedical and Behavioral Research Innovations to Ensure Equity in Maternal and Child Health
the National Institutes of Health has recently partnered with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to establish the Biomedical and Behavioral Research Innovations to Ensure Equity (BRITE) in Maternal and Child Health Grant Program.

---

Lifespan Respite Care Program - Technical Assistance Resource Center
In keeping with this mission, the Administration on Aging has recently announced the constitution of the Lifespan Respite Care Program - Technical Assistance Resource Center wherein it aims to invite applications for a competitive grant opportunity for implementing the requirements of the Technical Assistance Resource Center (TARC) as authorized in the Lifespan Respite Care Act of 2006.

---

Development of Therapeutics and Diagnostics for Biodefense Program
The National Institutes of Health, in partnership with the National Institute of Allergy and Infectious Diseases(NIAID), has established the Development of Therapeutics and Diagnostics for Biodefense Program in an attempt to seek research proposals that desire to support the development of lead candidate diagnostics or therapeutics against NIAID Category A, B, or C priority agents.

---